We commend Porth et al. for their timely and insightful study, "Gaps in Glycaemic Monitoring and Underuse of Cardioprotective Glucose-lowering Agents," which elucidates critical deficiencies in European inpatient diabetes management through the EFIM Diabesity Day Survey 2024[1]. This cross-sectional analysis of 207 patients across eight hospitals underscores two systemic failures: the underutilization of cardioprotective agents and inconsistent glycaemic monitoring practices[1]. With the global prevalence of diabetes and obesity rising precipitously, these gaps align with international guidelines, including the Korean Diabetes Association (KDA) recommendations for rigorous screening and individualized care, necessitating urgent multidisciplinary solutions[2].
